| Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and … S O'Reilly, M Ciechomska, R Cant, JM van Laar Journal of Biological Chemistry 289 (14), 9952-9960, 2014 | 240 | 2014 |
| Interleukin‐6: a new therapeutic target in systemic sclerosis? S O'reilly, R Cant, M Ciechomska, JM Van Laar Clinical & Translational Immunology 2 (4), e4, 2013 | 110 | 2013 |
| Interleukin-6, its role in fibrosing conditions S O’Reilly, M Ciechomska, R Cant, T Hügle, JM van Laar Cytokine & growth factor reviews 23 (3), 99-107, 2012 | 103 | 2012 |
| DNA methylation as a future therapeutic and diagnostic target in rheumatoid arthritis M Ciechomska, L Roszkowski, W Maslinski Cells 8 (9), 953, 2019 | 100 | 2019 |
| MiR-29a reduces TIMP-1 production by dermal fibroblasts via targeting TGF-β activated kinase 1 binding protein 1, implications for systemic sclerosis M Ciechomska, S O’Reilly, M Suwara, K Bogunia-Kubik, JM van Laar PloS one 9 (12), e115596, 2014 | 95 | 2014 |
| IL-13 mediates collagen deposition via STAT6 and microRNA-135b: a role for epigenetics S O’Reilly, M Ciechomska, N Fullard, S Przyborski, JM Van Laar Scientific reports 6 (1), 25066, 2016 | 86 | 2016 |
| Significance of Polymorphism and Expression of miR-146a and NFkB1 Genetic Variants in Patients with Rheumatoid Arthritis K Bogunia-Kubik, B Wysoczańska, D Piątek, M Iwaszko, M Ciechomska, ... Archivum immunologiae et therapiae experimentalis 64, 131-136, 2016 | 76 | 2016 |
| Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors M Ciechomska, CA Huigens, T Hügle, T Stanly, A Gessner, B Griffiths, ... Annals of the rheumatic diseases 72 (8), 1382-1389, 2013 | 72 | 2013 |
| Serum amyloid A induces interleukin‐6 in dermal fibroblasts via Toll‐like receptor 2, interleukin‐1 receptor‐associated kinase 4 and nuclear factor‐κB S O'Reilly, R Cant, M Ciechomska, J Finnigan, F Oakley, S Hambleton, ... Immunology 143 (3), 331-340, 2014 | 70 | 2014 |
| Changes in MiRNA-5196 expression as a potential biomarker of anti-TNF-α therapy in rheumatoid arthritis and ankylosing spondylitis patients M Ciechomska, K Bonek, M Merdas, P Zarecki, J Swierkot, P Gluszko, ... Archivum immunologiae et therapiae experimentalis 66, 389-397, 2018 | 51 | 2018 |
| Histone demethylation and toll‐like receptor 8–dependent cross‐talk in monocytes promotes transdifferentiation of fibroblasts in systemic sclerosis via Fra‐2 M Ciechomska, S O'Reilly, S Przyborski, F Oakley, K Bogunia‐Kubik, ... Arthritis & Rheumatology 68 (6), 1493-1504, 2016 | 50 | 2016 |
| Role of toll-like receptors in systemic sclerosis M Ciechomska, R Cant, J Finnigan, JM van Laar, S O'Reilly Expert reviews in molecular medicine 15, e9, 2013 | 45 | 2013 |
| Current frontiers in systemic sclerosis pathogenesis M Ciechomska, J van Laar, S O'Reilly Experimental dermatology 24 (6), 401-406, 2015 | 41 | 2015 |
| Age‐related changes in the occurrence and characteristics of thymic CD4+ CD25+ T cells in mice E Kozlowska, M Biernacka, M Ciechomska, N Drela Immunology 122 (3), 445-453, 2007 | 40 | 2007 |
| Emerging role of epigenetics in systemic sclerosis pathogenesis M Ciechomska, JM Van Laar, S O'reilly Genes & Immunity 15 (7), 433-439, 2014 | 38 | 2014 |
| Epigenetic modulation as a therapeutic prospect for treatment of autoimmune rheumatic diseases M Ciechomska, S O’Reilly Mediators of inflammation 2016, 2016 | 34 | 2016 |
| Small molecule inhibitors in the treatment of rheumatoid arthritis and beyond: Latest updates and potential strategy for fighting COVID-19 M Massalska, W Maslinski, M Ciechomska Cells 9 (8), 1876, 2020 | 32 | 2020 |
| The role of micro RNA‐5196 in the pathogenesis of systemic sclerosis M Ciechomska, P Zarecki, M Merdas, J Swierkot, E Morgiel, P Wiland, ... European Journal of Clinical Investigation 47 (8), 555-564, 2017 | 29 | 2017 |
| Tuning monocytes and macrophages for personalized therapy and diagnostic challenge in rheumatoid arthritis L Roszkowski, M Ciechomska Cells 10 (8), 1860, 2021 | 28 | 2021 |
| Biologic drugs for rheumatoid arthritis in the context of biosimilars, genetics, epigenetics and COVID-19 treatment K Bonek, L Roszkowski, M Massalska, W Maslinski, M Ciechomska Cells 10 (2), 323, 2021 | 23 | 2021 |
Jacob M van LaarUniversity Medical Center UtrechtVahvistettu sähköpostiosoite verkkotunnuksessa umcutrecht.nl
